Anti-Stroke Profile of Thiazolidin-4-One Derivatives in Focal Cerebral Ischemia Model in Rat

Chemical Biology and Drug Design

Volumn 78, Issue 3, 2011, Pages 445-453

  Raghubir, Ram ^a   Verma, Rajkumar ^a   Samuel, Sheeba S ^a   Raza, Saman ^a   Haq, Wajahul ^a   Katti, Seturam B ^a  

^a CENTRAL DRUG RESEARCH INSTITUTE   (India)

Author keywords

Cerebral ischemia; Neuroprotection; PPAR agonist; Rosiglitazone; Thiazolidin 4 one

Indexed keywords

4 THIAZOLIDINONE DERIVATIVE; GLUTAMIC ACID; GLUTATHIONE; ROSIGLITAZONE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN INJURY; BRAIN ISCHEMIA; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFICACY; DRUG SYNTHESIS; ENZYME ACTIVITY; MALE; NEUROPROTECTION; NONHUMAN; PHARMACOPHORE; PRIORITY JOURNAL; RAT;

ANIMALS; BRAIN; BRAIN ISCHEMIA; EXCITATORY AMINO ACID TRANSPORTER 2; GLUTAMIC ACID; GLUTATHIONE; MALE; NEUROPROTECTIVE AGENTS; PPAR GAMMA; RATS; RATS, SPRAGUE-DAWLEY; THIAZOLIDINEDIONES;

RATTUS;

EID: 80051596267     PISSN: 17470277     EISSN: 17470285     Source Type: Journal    
DOI: 10.1111/j.1747-0285.2011.01153.x     Document Type: Article

References (39)

1. Mehta S.L., Manhas N., Raghubir R. (2007) Molecular targets in cerebral ischemia for developing novel therapeutics. Brain Res Rev;54:34-66.
2. Vemuganti R. (2008) Therapeutic Potential of PPARγ Activation in Stroke. PPAR Res;2008:1-9.
3. Nakka V.P., Gusain A., Mehta S.L., Raghubir R. (2008) Molecular mechanisms of apoptosis in cerebral ischemia: multiple neuroprotective opportunities. Mol Neurobiol;37:7-38.
4. Romera C., Hurtado O., Mallolas J., Pereira M.P., Morales J.R., Romera A., Serena J., Vivancos J., Nombela F., Lorenzo P., Lizasoain I., Moro M.A. (2007) Ischemic preconditioning reveals that GLT1/EAAT2 glutamate transporter is a novel PPARgamma target gene involved in neuroprotection. J Cereb Blood Flow Metab;27:1327-1338.
5. Bordet R., Ouk T., Petrault O., Gele P., Gautier S., Laprais M., Deplanque D., Duriez P., Staels B., Fruchart J.C., Bastide M. (2006) PPAR: a new pharmacological target for neuroprotection in stroke and neurodegenerative diseases. Biochem Soc Trans;34:1341-1346.
6. Sundararajan S., Gamboa J.L., Victor N.A., Wanderi E.W., Lust W.D., Landreth G.E. (2005) Peroxisome proliferator-activated receptor-gamma ligands reduce inflammation and infarction size in transient focal ischemia. Neuroscience;130:685-696.
7. Shimazu T., Inoue I., Araki N., Asano Y., Sawada M., Furuya D., Nagoya H., Greenberg J.H. (2005) A peroxisome proliferator-activated receptor-gamma agonist reduces infarct size in transient but not in permanent ischemia. Stroke;36:353-359.
8. Tureyen K., Kapadia R., Bowen K.K., Satriotomo I., Liang J., Feinstein D.L., Vemuganti R. (2007) Peroxisome proliferator-activated receptor-gamma agonists induce neuroprotection following transient focal ischemia in normotensive, normoglycemic as well as hypertensive and type-2 diabetic rodents. J Neurochem;101:41-56.
9. Hyong A., Jadhav V., Lee S., Tong W., Rowe J., Zhang J.H., Tang J. (2008) Rosiglitazone, a PPAR gamma agonist, attenuates inflammation after surgical brain injury in rodents. Brain Res;1215:218-224.
10. Victor N.A., Wanderi E.W., Gamboa J., Zhao X., Aronowski J., Deininger K., Lust W.D., Landreth G.E., Sundararajan S. (2006) Altered PPARgamma expression and activation after transient focal ischemia in rats. Eur J Neurosci;24:1653-1663.
11. Luo Y., Yin W., Signore A.P., Zhang F., Hong Z., Wang S., Graham S.H., Chen J. (2006) Neuroprotection against focal ischemic brain injury by the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone. J Neurochem;97:435-448.
12. Patzer A., Zhao Y., Stock I., Gohlke P., Herdegen T., Culman J. (2008) Peroxisome proliferator-activated receptorsgamma (PPARgamma) differently modulate the interleukin-6 expression in the peri-infarct cortical tissue in the acute and delayed phases of cerebral ischaemia. Eur J Neurosci;28:1786-1794.
13. Young P.W., Buckle D.R., Cantello B.C., Chapman H., Clapham J.C., Coyle P.J., Haigh D. et al. (1998) Identification of high-affinity binding sites for the insulin sensitizer rosiglitazone (BRL-49653) in rodent and human adipocytes using a radioiodinated ligand for peroxisomal proliferator-activated receptor gamma. J Pharmacol Exp Ther;284:751-759.
14. Dow R.L., Bechle B.M., Chou T.T., Clark D.A., Hulin B., Stevenson R.W. (1991) Benzyloxazolidine-2, 4-diones as potent hypoglycemic agents. J Med Chem;34:1538-1544.
15. Goldstein S.W., McDermott R.E., Gibbs E.M., Stevenson R.W. (1993) Hydroxyurea derivatives as hypoglycemic agents. J Med Chem;36:2238-2240.
16. Shinkai H., Onogi S., Tanaka M., Shibata T., Iwao M., Wakitani K., Uchida I. (1998) Isoxazolidine-3, 5-dione and noncyclic 1, 3-dicarbonyl compounds as hypoglycemic agents. J Med Chem;41:1927-1933.
17. Abhinit M., Ghodke M., Pratima N.A. (2009) Exploring potential of 4-thiazolidinone: a brief review. Int J Pharmacy Pharm sci;1:47-64.
18. Prabhakar Y.S., Raja Solomon V., Gupta M.K., Katti S.B., QSAR (2006) Studies on thiazolidines: a biologically privlleged scaffold. In: Gupta S.P., editor. QSAR and Molecular Modeling in Heterocyclinc Drugs II sries: Topic in Heterocyclic Chemistry vol. 4. New York, USA: Springer; p. 161-249.
19. Verma R., Mishra V., Sasmal D., Raghubir R. (2010) Pharmacological evaluation of glutamate transporter 1 (GLT-1) mediated neuroprotection following cerebral ischemia/reperfusion injury. Eur J Pharmacol;638:65-71.
20. Bederson J.B., Pitts L.H., Germano S.M., Nishimura M.C., Davis R.L., Bartkowski H.M. (1986) Evaluation of 2., 3., 5-triphenyltetrazolium chloride as a stain for detection and quantification of experimental cerebral infarction in rats. Stroke;17:1304-1308.
21. Longa E.Z., Weinstein P.R., Carlson S., Cummins R. (1989) Reversible middle cerebral artery occlusion without craniectomy in rats. Stroke;20:84-91.
22. Nakka V.P., Gusain A., Raghubir R. (2009) Endoplasmic reticulum stress plays critical role in brain damage after cerebral ischemia/reperfusion in rats. Neurotox Res;17:189-202.
23. Colado M.I., O'Shea E., Granados R., Misra A., Murray T.K., Green A.R. (1997) A study of the neurotoxic effect of MDMA ('ecstasy') on 5-HT neurones in the brains of mothers and neonates following administration of the drug during pregnancy. Br J Pharmacol;121:827-833.
24. Anderson B.B., Carandina G., Lucci M., Perry G.M., Vullo C. (1987) Red-cell GSH regeneration and glutathione reductase activity in G6PD variants in the Ferrara area. Br J Haematol;67:459-466.
25. Xu N.J., Bao L., Fan H.P., Bao G.B., Pu L., Lu Y.J., Wu C.F., Zhang X., Pei G. (2003) Morphine withdrawal increases glutamate uptake and surface expression of glutamate transporter GLT1 at hippocampal synapses. J Neurosci;23:4775-4784.
26. Henn F.A., Hemberger A. (1971) Glial cell function: uptake of transmitter substances. Proc Nat Acad Sci;68:2686-2690.
27. Henke B.R., Blanchard S.G., Brackeen M.F., Brown K.K., Cobb J.E., Collins J.L., Harrington W.W. Jr et al. (1998) N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 1 Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents. J Med Chem;41:5020-5036.
28. Bolay H., Dalkara T. (1998) Mechanisms of motor dysfunction after transient MCA occlusion: persistent transmission failure in cortical synapses is a major determinant. Stroke;29:1988-1993.
29. Torp R., Lekieffre D., Levy L.M., Haug F.M., Danbolt N.C., Meldrum B.S., Ottersen O.P. (1995) Reduced post-ischemic expression of a glial glutamate transporter, GLT1, in the rat hippocampus. Exp Brain Res;103:51-58.
30. Hirsch E.C., Breidert T., Rousselet E., Hunot S., Hartmann A., Michel P.P. (2003) The role of glial reaction and inflammation in Parkinson's disease. Ann N Y Acad Sci;991:214-228.
31. Zhao Y., Patzer A., Gohlke P., Herdegen T., Culman J. (2005) The intracerebral application of the PPARgamma-ligand pioglitazone confers neuroprotection against focal ischaemia in the rat brain. Eur J Neurosci;22:278-282.
32. Park S.W., Yi J.H., Miranpuri G., Satriotomo I., Bowen K., Resnick D.K., Vemuganti R. (2007) Thiazolidinedione class of peroxisome proliferator-activated receptor gamma agonists prevents neuronal damage, motor dysfunction, myelin loss, neuropathic pain, and inflammation after spinal cord injury in adult rats. J Pharmacol Exp Ther;320:1002-1012.
33. Zhao Y., Patzer A., Herdegen T., Gohlke P., Culman J. (2006) Activation of cerebral peroxisome proliferator-activated receptors gamma promotes neuroprotection by attenuation of neuronal cyclooxygenase-2 overexpression after focal cerebral ischemia in rats. FASEB J;20:1162-1175.
34. Sener G., Tugtepe H., Yuksel M., Cetinel S., Gedik N., Yegen B.C. (2006) Resveratrol improves ischemia/reperfusion-induced oxidative renal injury in rats. Arch Med Res;37:822-829.
35. Fong W.H., Tsai H.D., Chen Y.C., Wu J.S., Lin T.N. (2010) Anti-apoptotic actions of PPAR-gamma against ischemic stroke. Mol Neurobiol;41:180-186.
36. Zhao X., Strong R., Zhang J., Sun G., Tsien J.Z., Cui Z., Grotta J.C., Aronowski J. (2009) Neuronal PPARgamma deficiency increases susceptibility to brain damage after cerebral ischemia. J Neurosci;29:6186-6195.
37. Bagi Z., Koller A., Kaley G. (2004) PPARgamma activation., by reducing oxidative stress., increases NO bioavailability in coronary arterioles of mice with Type 2 diabetes. Am J Physiol Heart Circ Physiol;286:H742-H748.
38. Orsini F., Bombieri G., Benetello F., Vigorita M.G., Previtera T. (1995) Future contributions to Journal of Chemical Crystallograpy. J Chem Crystallogr;25:527.
39. Folbergrova J., Kiyota Y., Pahlmark K., Memezawa H., Smith M.L., Siesjo B.K. (1993) Does ischemia with reperfusion lead to oxidative damage to proteins in the brain? J Cereb Blood Flow Metab;13:145-152.